A Silver Lining in Cancer; Dedicated Care for DCIS; New Vaccination Initiative

A patient with breast cancer discovers the silver lining in her diagnosis and treatment. (ASCO Connection)

Innovent Biologics announced that the PD-1 inhibitor sintilimab plus bevacizumab biosimilar (Byvasda) significantly improved progression-free survival in advanced EGFR-positive non-small cell lung cancer that progressed on prior EGFR-inhibitor therapy.

By means of a complete response letter, the FDA requested additional information about the treatment effect of narsoplimab, which targets the lectin pathway in the complement system, in hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to Omeros Corporation.

Genetic testing of the siblings of newborns with cancer-predisposition genes might reduce mortality from rare pediatric cancers by 50%, according to an NIH-funded study. (JAMA Network Open)

David Livingston, MD, whose research helped pave the way to new insights and treatment for breast and ovarian cancers, died unexpectedly on Oct. 17. (Dana-Farber Cancer Institute)

Learning the virtues of Ruth through a cancer patient. (Journal of Clinical Oncology)

Biennial breast cancer screening starting at age 40 in Black women would reduce the racial disparity in breast cancer mortality by 40%. (Annals of Internal Medicine)

The selective estrogen receptor degrader elacestrant significantly improved progression-free survival in patients with advanced/metastatic hormone receptor-positive/HER2-negative breast cancer, including the subgroup with estrogen receptor 1 mutations, Radius Health and the Menarini Group announced.

A phase II trial of PDS0101, which targets human papillomavirus-expressing tumors, has temporarily suspended patient recruitment for administrative reasons, not safety or efficacy concerns, according to PDS Biotech.

A study involving preclinical models of cancer suggested that a low glycemic diet alters lipid metabolism to influence tumor growth. (Nature)

Durvalumab (Imfinzi) plus a single priming dose of tremelimumab significantly improved overall survival versus sorafenib (Nexavar) as initial treatment for unresectable liver cancer, AstraZeneca announced.

Dana-Farber Brigham Cancer Center has launched a dedicated clinical program for ductal carcinoma in situ.

The American Society of Clinical Oncology has joined forces with the Council of Medical Specialty Societies in an initiative to increase vaccination rates in high-risk adults, including patients with cancer.

Patients who received pegylated interferon-alfa along with a bone marrow transplant had a lower risk of leukemia recurrence. (Michigan Health, Blood Advances)

A web-based docuseries supported by Merck has the goal of raising awareness about triple-negative breast cancer among Black women. (FiercePharma)

Please enable JavaScript to view the comments powered by Disqus.